(EN) (i2)
mwu
ft
iz
s-5
iv
x
m
£
titz
s
issaj
n
(19)
##Mnttffi*r*t«lllS
IHMMi
(43)
m&'&m
a
2013
^
8
R
22
0(22.08.2013)
WIPOIPCT
(10)
WO
2013/122135
A1
(51)
SURftfr#®:
A61K31/7068
(2006.01)
A61K
9/14
(2006.01)
A61K9/20
(2006.01)
A61K9/30
(2006.01)
A61K31/513
(2006.01)
A61K
47/10
(2006.01)
A61K
47/12
(2006.01)
A61K
47/26
A61K
47/32
A61K
47/36
A61K
47/38
A61K
47/44
A61P
35/00
A61P
43/00
(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)
(21)
(22)
(25)
(26)
(30)
(71)
(72)
0:
PCT/JP2013/053514
2013
^
2
M
14
0(14.02.2013)
0*1S
0*lg
X
—
£
:
2012-031144 2012
2
M
15
0(15.02.2012)
JP
ttiJi
A:
AII
II
qq
I
H
S
#
-fiCI'A
I
HO
PHARMA
CEUTICAL CO.,
LTD.)
[JP/JP];
T
1018444
-f-^Ba
EWBaSSBT
1-27
Tokyo
(JP).
%
BJ
#:
A
S
If
A
(OHNISHI,
Yoshito);
T
7710194
Hft!RISftrfTJIIrtnr¥5£5iF2
2
4-2
*1!
Tokushima
(JP).
MB
(OGATA,
Tetsuo);
T7710194
rfT
Jl|
fa Hi
¥5351?
2
2
4-2
Tokushima
(JP).
(74)
ftiA:
PATENT
CORPORATE
BODY ARUGA PATENT
OFFICE);
T
1030013
&
E
0
Ai
EST
1
Tl
3#8^
iR(7)f!Aff^B7
tf
)l>
Tokyo
(JP).
(8i)
Jt^ia
(^ro&i^PBy,
IS
^
pj
ft
):
AE,
AG,
AL, AM,
AO,
AT,
AU,
AZ,
BA,
BB, BG, BH,
BN, BR, BW,
BY,
BZ,
CA, CH,
CL,
CN,
CO,
CR, CU,
CZ,
DE, DK, DM,
DO,
DZ,
EC, EE,
EG,
ES,
FI,
GB,
GD, GE,
GH,
GM, GT, HN, HR, HU, ID,
IL,
IN,
IS,
JP,
KE,
KG,
KM,
KN, KP, KR, KZ, LA,
LC,
LK,
LR,
LS, LT,
LU,
LY,
MA, MD, ME, MG, MK, MN,
MW,
MX,
MY, MZ,
NA,
NG,
NI,
NO, NZ,
OM,
PA,
PE,
PG, PH,
PL,
PT, QA,
RO, RS, RU, RW,
SC, SD,
SE,
SG,
SK,
SL,
SM,
ST, SV, SY,
TH,
TJ,
TM,
TN, TR,
TT, TZ,
UA, UG,
US, UZ,
VC, VN,
ZA,
ZM, ZW.
(84)
(asrofci^isy
>
±T(Dmm(Dfcm%
V&tf
nlfb):
ARIPO (BW,
GH,
GM, KE,
LR,
LS,
MW,
MZ,
NA, RW,
SD,
SL, SZ,
TZ,
UG,
ZM, ZW),
n.
—
V
7
(AM,
AZ,
BY,
KG,
KZ,
RU,
TJ,
TM),
3
—
•
V
/
^
(AL,
AT, BE, BG,
CH,
CY,
CZ,
DE, DK,
EE, ES,
FI,
FR,
GB,
GR,
HR,
HU,
IE, IS,
IT,
LT,
LU,
LV,
MC,
MK,
MT,
NL,
NO,
PL, PT,
RO, RS,
SE,
SI, SK, SM,
TR),
OAPI
(BF, BJ,
CF,
CG,
CI, CM,
GA,
GN, GQ,
GW, ML, MR,
NE,
SN,
TD,
TG).
-
(mm
2\
^0))
<
(54)
Title:
ORAL
PHARMACEUTICAL
COMPOSITION
(54)f6IE©€ffc:igPfflEHfflj$!|*|
H
( >
57
Abstract:
Provided
is
an
FTD-
and TPI-containing
oral
pharmaceutical composition which
can
be
orally
administered and
is
i-H
stable
even under high
humidity conditions.
This
oral
pharmaceutical composition contains
a,a,a-trifluorothymidine
and 5-chloro-6-
rn
(
2
-iminopyrrolidine-1-yl)
methyl-2,4
(1H,
3H)-pyrimidine
dione
hydrochloride
as
the
active ingredient,
and
contains substantially
i-H
no
additives comprising metal
salts.
S
(57)®$:
\
/-s
-So
a, a,
a-
MJ
£
V
5
- - -
<7
• •
6
(
2
-
>T
£
/
t?
•
U
V
>-
1
-
•<
JU)
*T)l>
y
-2,
4
(1
H,
3
H)
—
tfg
5